Bioventus Shares Fall on 3Q Sales Miss, Cut to Outlook

By Elias Schisgall

Shares of Bioventus fell after the company cut its outlook and reported sales in the third quarter that missed analyst expectations.

The stock fell 11% to $11.75 in after-hours trading on Monday. Shares closed down 1.3% at $13.15 and had risen 77% year-to-date through the close.

The company on Monday reported a profit of $6 million, or 8 cents a share, compared with a profit of $3.2 million, or 5 cents a share, a year earlier.

Stripping out certain one-time items, adjusted earnings were 17 cents a share. Analysts polled by FactSet were expecting 15 cents a share.

Net sales rose to $142.4 million from $138.7 million. Analysts had been expecting $149.5 million.

Bioventus also cut its net sales outlook for the full year. It projected 2026 net sales of between $590 million and $595 million, down from previous guidance in a range of $600 million to $610 million. Analysts currently expect $604.8 million in net sales.

The company reaffirmed its guidance for adjusted earnings this year between 75 cents and 79 cents a share. Analysts are expecting 78 cents a share.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

November 02, 2026 18:33 ET (23:33 GMT)